Clinical Trials Logo

Filter by:
NCT ID: NCT03836040 Not yet recruiting - Migraine Clinical Trials

Efficacy and Safety of Erenumab in Pediatric Subjects With Episodic Migraine

OASIS (EM)
Start date: June 6, 2019
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with episodic migraine. The study hypothesis is that in pediatric subjects with episodic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).

NCT ID: NCT03833271 Recruiting - Clinical trials for Juvenile Idiopathic Arthritis

The Efficacy of Influenza Vaccine Program in Children With Juvenile Idiopathic Arthritis. A Single Centre Results From Hungary

Start date: October 28, 2018
Phase: Early Phase 1
Study type: Interventional

The aim of our study is to compare the immune function of patient treated with DMARD (methotrexate), or tumor necrosis factor (TNF)-alpha inhibitor (adalimumab) to healthy children. The study consists of three parts. In each part physical examination and routine laboratory tests are done. At the first examination flow cytometry analysis is performed, after that the participants are immunized with influenza (3Fluart) vaccine. At part two and three further flow cytometry is carried out and seroconversion is measured.

NCT ID: NCT03832998 Not yet recruiting - Migraine Clinical Trials

Efficacy and Safety of Erenumab in Pediatric Subjects With Chronic Migraine

OASIS (CM)
Start date: June 6, 2019
Phase: Phase 3
Study type: Interventional

This study will evaluate the efficacy and safety of erenumab in migraine prevention in children (6 to <12 years) and adolescents (12 to <18 years) with chronic migraine. The study hypothesis is that in pediatric subjects with chronic migraine, the combined erenumab dose group has a greater reduction from baseline to week 9 through week 12 (month 3) in monthly migraine days (MMDs) when compared with placebo in the double-blind treatment phase (DBTP).

NCT ID: NCT03831191 Not yet recruiting - Atopic Dermatitis Clinical Trials

A Study of LY3375880 in Adults With Moderate-to-Severe Atopic Dermatitis

ADmIRe
Start date: February 12, 2019
Phase: Phase 2
Study type: Interventional

The reason for this study is to see if the study drug LY3375880 is safe and effective in adults with moderate-to-severe atopic dermatitis (AD).

NCT ID: NCT03830866 Not yet recruiting - Clinical trials for Locally Advanced Cervical Cancer

Study of Durvalumab With Chemoradiotherapy for Women With Locally Advanced Cervical Cancer (CALLA)

CALLA
Start date: February 1, 2019
Phase: Phase 3
Study type: Interventional

This is a randomized, multi-center, double-blind, placebo-controlled, global, Phase III study to determine the efficacy and safety of durvalumab + Chemoradiotherapy versus Chemoradiotherapy alone as treatment in Women With Locally Advanced Cervical Cancer

NCT ID: NCT03830281 Not yet recruiting - Clinical trials for Type 1 Diabetes Mellitus

A Study Comparing LY900014 to Insulin Lispro (Humalog) in Adults With Type 1 Diabetes Using Insulin Pump Therapy

PRONTO-Pump-2
Start date: February 14, 2019
Phase: Phase 3
Study type: Interventional

The reason for this study is to compare the study drug LY900014 to insulin lispro (Humalog) when both are used in insulin pump therapy in adults with type 1 diabetes (T1D).

NCT ID: NCT03826511 Completed - Knee Osteoarthritis Clinical Trials

The Effects of Tiszasüly and Kolop Mud-pack Therapy in Knee Osteoarthritis

Start date: August 2016
Phase: N/A
Study type: Interventional

In this double-blind, randomized, follow-up study investigators evaluated and compared the effects of Tiszasüly and Kolop mud-pack therapy on pain, function and quality of life in patients with knee osteoarthritis. 30 patients were treated with Tiszasüly hot mud-pack (Group 1), 30 patients with Kolop hot mud-pack (Group 2) for 10 working days. Knee pain, function a nd qualitiy of life were measured at baseline, at the end of treatment and 3 months later.

NCT ID: NCT03823378 Not yet recruiting - Clinical trials for Rheumatoid Arthritis (RA)

A Study in Rheumatoid Arthritis Patients Who Have Completed a Preceding Study With ABBV-105 Given Alone or in Combination With Upadacitinib

Start date: May 6, 2019
Phase: Phase 2
Study type: Interventional

This is a long-term extension (LTE) study to assess the safety, tolerability abd efficacy of ABBV-105 and ABBV-599 in Rheumatoid Arthritis (RA) participants who have completed M16-063.

NCT ID: NCT03821415 Recruiting - Dry Eye Syndromes Clinical Trials

Effects of RP101 in Post-menopausal Women With Dry Eye Syndrome

Start date: January 18, 2019
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to establish whether RP101 can reduce symptoms of dry eye syndrome in post-menopausal women.

NCT ID: NCT03820830 Not yet recruiting - Clinical trials for Breast Cancer Recurrent

Palbociclib for HR Positive / HER2-negative Isolated Locoregional Recurrence of Breast Cancer

POLAR
Start date: May 1, 2019
Phase: Phase 3
Study type: Interventional

POLAR is a phase III clinical trial, which will test the safety and efficacy of an investigational combination of drugs to learn whether the combination of drugs works for a specific cancer. Palbociclib (Ibrance®) is the name of the investigational agent, which is assessed together with standard anti-hormone therapy in this study. Palbociclib is used to treat patients with hormone receptor-positive / HER2-negative breast cancer which has spread beyond the original tumor and/or to other organs. During this study, anti-hormone therapy will consist of either a selective estrogen receptor modulator (such as tamoxifen) or an aromatase inhibitor (anastrozole, letrozole, exemestane) or fulvestrant (Faslodex®). Premenopausal women and men may also receive a drug called an LHRH (luteinizing hormone-releasing hormone) agonist by injection. It is standard of care for people with hormone receptor positive breast cancer to take anti-hormone therapy. The study doctor will determine the type of standard anti-hormone therapy that will be given during this trial. The purpose of the POLAR study is to compare the effect of using 3 years of palbociclib in combination with standard anti-hormone therapy with standard anti-hormone therapy alone and to evaluate the time until the breast cancer returns, if it does return.